Stem Cell Research

Axolotl Biologix to Exhibit at BIO International Convention 2017 in San Diego

 Axolotl Biologix to Exhibit at BIO International Convention 2017 in San Diego

Phoenix – June 12, 2017 - Axolotl Biologix, Inc., a biotech company that focuses on research and technology to enhance regenerative medicine, announced today that it will be exhibiting at the BIO Conference. The conference will be held June 19th-23rd at the San Diego Convention Center in San Diego, California. Axolotl Biologix will be exhibiting in the Arizona Pavilion at Booth 5519.

Axolotl Biologix’ CEO Bob Maguire stated, “We are excited to be a part of this event with over 17,000 attendees from around the world. We have dozens of meetings scheduled and are hoping to gain partnerships and opportunities to acquire more intellectual property.”

About Axolotl Biologix, Inc.

Axolotl Biologix, Inc. is a biotech company that develops and manufactures human cell and tissue products for orthopedic, wound care, podiatric, and aesthetic markets. The Company’s currently has two products to market. The first is it’s AxoBioFluid®, which is an amniotic allograft cryopreserved liquid that advances soft tissue repair, replacement, and reconstruction. The second is it’s AxoBioMembrane™, which is an amniotic allograft membrane used for wound care and surgical applications. The Company’s vision is to be an innovative and global leader in regenerative medicine through research, technology, and clinical application. 

For more information, please visit Axolotl Biologix’ website at www.axobio.com

SOURCE Axolotl Biologix, Inc.

Media:

PR@axobio.com

602-334-1298 ext. 1

Axolotl Biologix Appoints Robert S. Kellar Ph.D., as Chief Science Officer

Phoenix – March 9, 2017 -- Axolotl Biologix, an innovator in regenerative medicine technologies that improve patient outcomes with less pain and lower costs, today announced the appointment of Robert S. Kellar, Ph.D., as Chief Science Officer. Dr. Kellar will be overseeing Axolotl Biologix’s research and product development efforts, bringing over 16 years of research and clinical development experience from medical device and biotechnology companies.

Most recently, Dr. Kellar served as an Advisory Board Member for Protein Genomics, Inc., a biotechnology company that focuses on research and development of biopolymers and their applications in wound healing, tissue regeneration, dermal fillers, and personal care markets. Dr. Kellar had a key role for building out the research program for Protein Genomics’ Elastatropin® an extracellular matrix protein that is an extremely important component of skin that provides strength and elasticity. 

Dr. Kellar will continue as an Associate Professor of Practice in Biological Sciences at the Center for Bioengineering Innovation at Northern Arizona University, and as the Co-Director of the Bioengineering PhD Program, the Co-Director of the Imaging & Histology Core Facility, and an adjunct faculty member in Mechanical Engineering. Dr. Kellar's academic laboratory is called the Tissue Engineering & Regenerative Medicine (TERM) Laboratory. His lab focuses on biomaterials, biocompatibility, cell & tissue culture, stem cell biology, and wound healing.

Dr. Kellar is the Founder and President of Development Engineering Sciences, LLC, a biomedical consulting firm. He has experience in the development and regulatory approval of medical devices, cell-based products, and tissue engineered technology. Previously, Dr. Kellar was VP of Research and Development at Histogen, Inc. where he led multi-functional project teams for all aspects of product development. Prior to Histogen, Dr. Kellar was a product specialist for the first FDA-approved thoracic endograft at W.L. Gore and Associates where he served in a lead role in development, regulatory, clinical trials, marketing, sales, and business for the thoracic device and the product portfolio. Previous to this position, Dr. Kellar was a product specialist for the Global Oral Health Business at W.L. Gore & Associates (both Gore-Tex® Regenerative Membranes and the entire resorbable membrane portfolio). Prior to Gore, at Advanced Tissue Sciences, Inc. he led cardiovascular research programs and managed the Anginera® program.

Dr. Kellar previously served on the Scientific Advisory Board for Theregen and the Advisory Board for Flagship Biosciences, a digital pathology company he helped co-found. He currently serves on the Scientific Advisory Board for MyoStim, the Board of Directors for the Surfaces in Biomaterials Foundation, the Advisory Board for Protein Genomics, and the Advisory Board for the California Stock Xchange. He earned his Ph.D. in 2001 in Physiological Sciences from the University of Arizona in the Biomedical Engineering Laboratory of Dr. Stuart K. Williams. Dr. Kellar is 42 years old.

“The role of biologics in regenerative medicine is one of the most promising new avenues for dramatic improvements in patient outcomes and comfort in the treatment for burns, surgical resections, trauma, and chronic wounds, as well as aesthetic medicine,” said Dr. Kellar. “I look forward to helping Axolotl Biologix rapidly move into a leadership position for research, development, and the clinical applications of new regenerative biotechnologies.”

About Axolotl Biologix, Inc.

Axolotl Biologix, Inc., is a developer of innovative regenerative human cell and tissue medical technologies that is disrupting traditional painful and expensive treatment regimens for burn, surgical, trauma and chronic wounds. The company is rapidly building a portfolio of unique patented regenerative treatment products to improve patients’ outcomes with less pain and lower costs. Founded in 2016 by Bob Maguire, AxoBio already has two products in production. AxoBioFluidTM, a cryopreserved liquid allograft, and AxoBioMembraneTM, an amniotic allograft membrane patch, are targeted to advancing soft tissue repair, replacement and reconstruction. For more information, please visit the company’s website at www.axobio.com. Axolotl Biologix is headquartered in Phoenix, 1637 Knudsen Drive, Phoenix, AZ 85027.

Media:

PR@axobio.com 

602-334-1298, x-11

Axolotl Biologix Signs Exclusive Worldwide License for Protein Genomics’ Elastatropin® to Drive Innovation in Regenerative Medicine Products for Wound Care

Phoenix – March 3, 2017 -- Axolotl Biologix, an innovator in regenerative medicine technologies that improve patient outcomes with less pain and lower costs, today announced that it has entered into an exclusive worldwide license agreement with Protein Genomics, Inc., for patents and manufacturing expertise for a biomimetic skin substitute that will accelerate the company’s pipeline of treatment products for burn, surgical, trauma and chronic wounds. The technology utilizes recombinantly-derived human tropoelastin (Elastropin®) to create a novel biomaterial to serve as a biomimetic skin substitute and acts as a delivery vehicle for human cells to a full thickness dermal wound.

Under the agreement, Axolotl Biologix is also acquiring Protein Genomics’ research laboratory, housed in the Northern Arizona Center for Entrepreneurship and Technology (NACET) business incubator in Flagstaff, Arizona. The Acquisition will augment Axolotl’s research and development capabilities driving the discovery of new regenerative technology that can be brought to market. Axolotl’s CEO, Bob Maguire, noted, “We are excited about this combination on several levels. Protein Genomics will allow us to accelerate our product pipeline, significantly strengthen our regenerative research efforts, and ratchet-up our expected revenue ramp.” Axolotl’s President, Phillip Larson added, “Our next generation product line will focus on novel product solutions for wound repair by incorporating tropoelastin, the precursor protein to elastin, an important extracellular matrix protein found in many organs, including skin, and provides needed elasticity and tensile strength. These two characteristics lead to greater success in healing wounds, which create better patient outcomes. That’s what Axolotl Biologix is all about.”

Dr. Burt Ensley, the CEO of Protein Genomics, will Chair Axolotl’s advisory board. Formerly of Amgen before founding Protein Genomics, Dr. Ensley brings tremendous knowledge, experience, and success with more than 21 patents and 30 peer-reviewed publications.

Scott Hathcock, president & CEO of NACET, noted the acquisition benefits the Northern Arizona region by keeping bioscience jobs in Flagstaff and adding Axolotl to the NACET portfolio of emerging companies. “We are focused on generating connections, capital and customers for our clients,” he said.  “This is another great example of the dynamic partnerships that are occurring between new companies to spur bioscience innovation and bring needed medical treatments to the market.”

Preclinical results demonstrate that the biomimetic skin substitute can be used as a sole therapy or in combination with stem cells to offer superior results to the current clinical standard of care for the closure of full thickness dermal wounds.

There will also be three new patent filings by Axolotl in the very near future.

About Axolotl Biologix, Inc.

Axolotl Biologix, Inc., is a developer of innovative regenerative human cell and tissue medical technologies that is disrupting traditional painful and expensive treatment regimens for burn, surgical, trauma and chronic wounds.  The company is rapidly building a portfolio of unique patented regenerative treatment products to improve patients’ outcomes with less pain and lower costs. Founded in 2016 by Bob Maguire and Phillip Larson, Axolotl Biologix already has two products in production. AxoBioFluidTM, a cryopreserved liquid allograft, and AxoBioMembraneTM, an amniotic allograft membrane patch is targeted to advancing soft tissue repair, replacement and reconstruction. For more information, please visit the company’s website at www.axobio.com.

About Protein Genomics, Inc.

Protein Genomics, Inc. is a Flagstaff, Arizona-based company that carries out research and development on sophisticated, high-performance biopolymers for applications in wound healing, tissue regeneration, dermal fillers, and personal care markets. For more information, please visit Protein Genomics’ website at www.proteingenomics.com

 

Media:

PR@axobio.com 

602-334-1298, x-11